Oslo, Norway, 30 June 2026: Photocure ASA (OSE: PHO) is today announcing that
Chief Financial Officer Erik Dahl will retire after nearly 14 years of dedicated
service to the company. To ensure a seamless transition, Erik will remain with
Photocure through the end of December 2026.
Erik's tenure has been instrumental in shaping Photocure's financial strength
and growth. "Erik has been a tremendous asset to our team, and we are deeply
grateful for everything he has contributed to the company and our shareholders
over the years," said Chief Executive Officer Dan Schneider. "He has guided our
financial organization through many significant milestones and helped build the
strong foundation we stand on today. We wish him the very best and are very
grateful for his service."
With ample time to ensure continuity, the search for Erik's successor is already
underway. CEO Dan Schneider will serve as acting CFO, with the full support of
Photocure's experienced finance team, until the new CFO is appointed.
For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Priyam Shah
Vice President Investor Relations
Tel : +17176815072
Email: priyam.shah@photocure.com
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II -
Issuer Rules.
g Act and Euronext Oslo Rule Book II -\
Issuer Rules.\